OPSIRIA

OPSIRIA was designed to fill an unmet need in the treatment of chronic noninfectious uveitis of the posterior segment (NIU-PS). OPSIRIA is the first and only targeted intravitreal (IVT) mechanistic target of rapamycin (mTOR) inhibitor that can help patients who suffer with this debilitating ocular disease.

Developed now approved campaign and launch materials.